Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: Potential benefits in bone and breast

Lin H. Soe, Gregory T. Wurz, Chiao Jung Kao, Michael W. DeGregorio

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60% of postmenopausal women. Ospemifene is the first and only nonestrogen compound approved for this indication. Compared with other approved SERMs, such as tamoxifen, toremifene, bazedoxifene, and raloxifene, the estrogen-like effects of ospemifene in the vaginal epithelium are unique. This review first discusses the rationale for developing ospemifene, including its mechanism of action, and then focuses on the clinical development of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Included are discussions of the effects of ospemifene on the endometrium, serum lipids, coagulation markers, bone, and breast cancer. In conclusion, ospemifene is a SERM with a unique estrogen agonist/antagonist tissue profile that was recently approved in the US for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women. Ospemifene warrants further clinical investigation for the treatment and prevention of osteoporosis and breast cancer.

Original languageEnglish (US)
Pages (from-to)605-611
Number of pages7
JournalInternational Journal of Women's Health
Volume5
Issue number1
DOIs
StatePublished - Sep 25 2013

    Fingerprint

Keywords

  • Breast cancer
  • Dyspareunia
  • Ospemifene
  • Osteoporosis
  • Vulvar and vaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Maternity and Midwifery

Cite this